{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096649","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.006407+00:00","generated_at":"2026-05-31T09:21:13.251264+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iterum reports Q2 2024 net loss $5.0M; PDUFA date Oct 25, 2024; AdCom Sept 9","bullets":["Net loss $5.0M Q2 2024 (vs $12.2M Q2 2023); cash $11.7M; expects runway into 2025 through PDUFA date.","FDA PDUFA action date October 25, 2024; Advisory Committee meeting September 9, 2024 on stewardship and patient population.","Closed rights offering August 9, 2024: $7.4M gross ($5.8M net) from 6.1M shares and warrants.","Received U.S. and Canadian patent allowances for sulopenem combinations expiring 2039-2041."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096649","json":"https://secwatch.observer/filing/0000950170-24-096649.json","markdown":"https://secwatch.observer/filing/0000950170-24-096649.md","text":"https://secwatch.observer/filing/0000950170-24-096649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024096649/0000950170-24-096649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024096649/itrm-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:21:13.251264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}